inVentiv Health, a global provider of clinical development and comprehensive commercialization services, announced expansion of compliance products and services to assist biopharmaceutical companies conducting non-interventional studies globally.
inVentiv Health, a global provider of clinical development and comprehensive commercialization services, announced expansion of compliance products and services to assist biopharmaceutical companies conducting non-interventional studies (NIS) globally. The announcement is related to changes in the EU Directive governing clinical trials, which takes effect May 2016. inVentiv Health believes the regulation could cause confusion around the conducting of non-interventional trials (also known as observational studies) because of vague regulatory language and establishment of a new category of trial with its own compliance requirements.
The new series of proprietary inVentiv Health resources are now available to address this issue and include:
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.